Metastasis

Oncology·MeSH: Neoplasm Metastasis

12 drugs in development·8 companies·6 clinical trials

Drug Pipeline by Phase

Approved(4)

Drug	Company
enzalutamide	Aptinyx Inc. (APTX)
enzalutamide	X4 Pharmaceuticals, Inc (XFOR)
pylarify	PROGENICS PHARMACEUTICALS INC (PGNX)
PYLARIFY	Lantheus Holdings, Inc. (LNTH)

Phase 3(1)

Drug	Company
177Lu-PSMA-I&T	KYNTRA BIO INC. (KYNB)

Phase 2(1)

Drug	Company
thor-707	Sanofi (SNY)

Phase 1(1)

Drug	Company
186rnl	PLUS THERAPEUTICS Inc. (PSTV)

Preclinical(2)

Drug	Company
SBI-183	AXIM BIOTECHNOLOGIES, INC. (AXIM)
SPX-1009	AXIM BIOTECHNOLOGIES, INC. (AXIM)

Unknown(1)

Drug	Company
Quiescin Sulfhydryl Oxidase 1 (QSOX1) license	AXIM BIOTECHNOLOGIES, INC. (AXIM)

Phase 1/Phase 2(2)

Drug	Company
anti-egfr antibody	Sanofi (SNY)
checkpoint inhibitor	Sanofi (SNY)

BioSniper tracks 12 drugs in development for Metastasis across 8 companies.

There are 6 clinical trials targeting Metastasis tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.